Home›Moderate To Strong Cyp2c19 Inducers

Moderate To Strong Cyp2c19 Inducers

1 interaction on record

Moderate To Strong Cyp2c19 Inducers + Mavacamten⛔Contraindicated

Concomitant use decreases mavacamten exposure and may reduce efficacy. Risk of heart failure may increase upon discontinuation. Contraindicated.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.